Fang Fund Partners
VC Fund
Chaoyang, China
Fang Fund Partners is a VC fund in Chaoyang focused on Medical and Health Care. Fang Fund is an equity investment fund and focuses on new economic fields, with a particular focus on big data, new media, intelligent technology (AR/VR), alternative energy resources, new materials and health care. Fang Fund Partners management team has years of successful business practices and venture investment experience. The team iscommitted to providing value-added services for invested companies, grafting quality social resources and aligning with the ecological industry chain.Fang Fund Partners vision is to become a fund that understands entrepreneurs best and helps them fulfill their dreams, in an effort to promote social progress and contribute to the welfare of human beings.Fang Fund Partners have unique insight into startup experience of honorable entrepreneurs. Fang Fund Partners AdvantagesA wide range of project sources：ν Over 30,000 quality project sources each yearν Parallel investment in Greater China, United States (East and West Coast), Israel and EuropeAbundant industrial resourcesν Fund’s partners include well-known entrepreneurs and industrial leadersν Fund’s management team has rich practical experience and industrial resourcesSolid value-adding servicesν Fang Fund Partners can support the invested companies in various aspects, such as capital, big data, human resources, marketing & sales strategy and industry cooperationν Fang Fund Partners can bring a broader international perspective and comprehensive strategic plans to our invested companies
- Total investments:
- 23
- Last investment:
- Lead investor:
- 35%
Last updated:
For AI agents: llms.txt
Industries Fang Fund Partners invests in
Stages Fang Fund Partners invests in
Countries Fang Fund Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Angel
- $425k–$425k
- Series A
- $1.4M–$16M
- Series B
- $2.8M–$21M
Investment Focus
Industry
- Medical 5 (22%)
- Health Care 5 (22%)
- Biotechnology 5 (22%)
- Pharmaceutical 5 (22%)
- Biopharma 3 (13%)
Stage
- Series A 9 (39%)
- Series B 6 (26%)
- Angel 3 (13%)
- Seed 1 (4%)
- Series C 1 (4%)
Country
- China 19 (83%)
- Israel 1 (4%)
- United States 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Eric Yang
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
Jenny Li
Partner
|
Partner | Total investments: 0 | Find email | |
|
Lethe Dong
Partner
|
Partner | Total investments: 0 | Find email | |
Mina Yu
Director
|
Director | Total investments: 0 | Find email | |
Mingfang Yu
Partner & Founder
|
Partner & Founder | Total investments: 0 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
SuperC
|
SuperC is an enterprise that specializes in the research and production of innovative nanomaterials. The company was founded in 2012 and is headquartered in Dongguan City, Guangdong, China. | Venture - Series Unknown / Feb 20, 2023 | |
Baikang Bio
|
Baikang Bio is an in vitro diagnostic and upstream core raw material developer of biological drugs. | $13.4M / Series A / Jan 12, 2023 | |
Bioantibody
|
Bioantibody is a high-tech biotechnology firm specializing in the research and development of antigens, antibodies, and downstream detection reagents for diagnosis and therapy. | $14.8M / Series A / Jan 12, 2023 | |
Boaoxin
|
Biosion is a biotech company focused on the development of biologics to treat resistant, relapsed, residual immune, and oncologic diseases. | Series B / Dec 28, 2022 | |
Business Leads World
|
4B Technologies is a biotech company that develops novel medicines for neurodegenerative diseases and neurological injuries. Its drug development focuses on reliving pain symptoms from nervous system diseases such as stroke and glaucoma, enabling healthcare professionals to prescribe more effective treatments to their patients.The company wasfounded in 2017 and is based in Suzhou, China. | $14.3M / Series B / Dec 12, 2022 | |
Easy Chat Technology
|
YiLiao Technology has focused on the online customer-acquiring AI intelligent customer service robot track, serving the "conversation-lead" conversion scenario in marketing. | $15.8M / Series B / Feb 21, 2022 | |
Aucta Pharmaceuticals China
|
Aucta Pharmaceuticals China is a provider of a drug development platform intended to improve drug delivery. | $15.6M / Series A / Nov 04, 2021 | |
Denovo Biopharma
|
Denovo Biopharma is a privately held biotech company providing a novel biomarker solution to personalize drug development. The core technology is the industry's first platform and algorithm to perform de novo genomic biomarker discovery retrospectively using archived clinical samples. This technology is especially useful for late stageclinical drugs that have completed trials with unsatisfactory efficacy. By identifying biomarkers correlated to patients' responsiveness to drug candidates retrospectively, our technology enables biotech and pharmaceutical companies to design new clinical trials in a targeted patient population to achieve significant efficacy and/or less adverse effects. Our platform can be broadly applied to biomarker discovery in many therapeutic areas, such as oncology, metabolic, cardiology, immunology and neurology. | $42.5M / Series D / Dec 10, 2020 | |
Yimi Station
|
Yimi Station is a modern catering management enterprise specializing in food industry technology. The core team of the company has accumulated nearly 20 years of industry, dedicated to the modernization of the development and implementation of top food, using the new Internet and Internet of Things. Technology, relying on multi-point distributionstructure, the closest to the consumer's gourmet intelligent kitchen cabinet and open food research and development platform, has become a new format of Chinese food, this model has been recognized by the industry and consumers after the launch, Yimi cloud standing here On the basis of this, we will continue to explore new scenes for campus feeding and become the pioneers of personalized dining on campus. | $2.9M / Series A / Dec 17, 2018 | |
TCR Cure
|
TCR Cure is an immunodiagnostic and accurate medical solutions provider company. | $1.4M / Series A / Dec 05, 2018 | |
| See all 23 investments → | |||
Co-Investors
Sangel Capital
3 deals together
Bondshine Capital
2 deals together
Evonik Venture Capital
2 deals together
Guoqian Venture Capital
2 deals together
Addor Capital
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Fang Fund Partners invest in?
Fang Fund Partners invests primarily in Medical, Health Care and Biotechnology startups, most often at Series A and Series B stage. Most of the 23 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Fang Fund Partners's check size?
Fang Fund Partners typically joins rounds of $425k–$425k at Angel, $1.4M–$16M at Series A and $2.8M–$21M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Fang Fund Partners participates in.
How do I contact Fang Fund Partners?
Public channels for Fang Fund Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Fang Fund Partners?
The team at Fang Fund Partners includes Eric Yang (Managing Director), Jenny Li (Partner) and Lethe Dong (Partner), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
